🇺🇸 FDA
Pipeline program

A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus

AUTO1-SL1

Phase 1 other active

Quick answer

A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus for Severe, Refractory Systemic Lupus Erythematosus is a Phase 1 program (other) at Autolus GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Autolus GmbH
Indication
Severe, Refractory Systemic Lupus Erythematosus
Phase
Phase 1
Modality
other
Status
active

Clinical trials